Crinetics Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Crinetics Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CRNX
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly.
CEOScott R. Struthers
CEOScott R. Struthers
Employees437
Employees437
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2008
Founded2008
Employees437
Employees437
CRNX Key Statistics
Market cap4.05B
Market cap4.05B
Price-Earnings ratio-9.41
Price-Earnings ratio-9.41
Dividend yield—
Dividend yield—
Average volume1.87M
Average volume1.87M
High today$43.95
High today$43.95
Low today$40.98
Low today$40.98
Open price$41.21
Open price$41.21
Volume1.42M
Volume1.42M
52 Week high$60.34
52 Week high$60.34
52 Week low$24.10
52 Week low$24.10
Stock Snapshot
As of today, Crinetics Pharmaceuticals(CRNX) shares are valued at $42.19. The company's market cap stands at 4.05B, with a P/E ratio of -9.41.
On 2025-11-15, Crinetics Pharmaceuticals(CRNX) stock moved within a range of $40.98 to $43.95. With shares now at $42.19, the stock is trading +3.0% above its intraday low and -4.0% below the session's peak.
Trading activity shows a volume of 1.42M, compared to an average daily volume of 1.87M.
Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $60.34 and a low of $24.10.
Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $60.34 and a low of $24.10.
Analyst ratings
88%
of 17 ratingsBuy
88.2%
Hold
11.8%
Sell
0%
People also own
Based on the portfolios of people who own CRNX. This list is generated using Robinhood data, and it’s not a recommendation.